NCT04684381View on ClinicalTrials.gov

Pharmacokinetics and Safety of Endari (L-glutamine) in Sickle Cell Disease Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

January 4, 2021

Primary Completion Date

June 30, 2021

Study Completion Date

June 30, 2021

Conditions
Sickle Cell DiseasePharmacokinetics
Interventions
DRUG

L-glutamine

Pharmacokinetic study

Trial Locations (1)

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

All Listed Sponsors
lead

Emmaus Medical, Inc.

INDUSTRY

NCT04684381 - Pharmacokinetics and Safety of Endari (L-glutamine) in Sickle Cell Disease Patients | Biotech Hunter | Biotech Hunter